Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Andre N. Kadima"'
Autor:
Andre N. Kadima, Marina Demcheva, David J. Cole, William E. Gillanders, Christophe L. Nguyen, Mark P. Rubinstein, Mohamed L. Salem, Yuehua Zhou, John N. Vournakis
Publikováno v:
The Journal of Immunology. 172:5159-5167
Interleukin-12 can act as a potent adjuvant for T cell vaccines, but its clinical use is limited by toxicity. Paracrine administration of IL-12 could significantly enhance the response to such vaccines without the toxicity associated with systemic ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f99d1a75d023b0445e5c29632e859b9
https://doi.org/10.4049/jimmunol.172.9.5159
https://doi.org/10.4049/jimmunol.172.9.5159
Autor:
Mohamed L. Salem, David J. Cole, Andre N. Kadima, William E. Gillanders, Michael I. Nishimura, Mark P. Rubinstein, Christophe L. Nguyen
Publikováno v:
The Journal of Immunology. 170:1209-1217
The adoptive transfer of tumor-specific T cells expanded in vitro can be of significant therapeutic value in select cancer patients. This strategy is limited though, as it is often difficult, if not impossible, to obtain T cells of clinical value. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a16873b2dd863ef6cc87ec11b8ee7ba6
https://doi.org/10.4049/jimmunol.170.3.1209
https://doi.org/10.4049/jimmunol.170.3.1209
Autor:
Christophe L. Nguyen, Andre N. Kadima, Mohamed L. Salem, Mark P. Rubinstein, Michael I. Nishimura, William E. Gillanders, David J. Cole
Publikováno v:
Cancer gene therapy. 16(2)
Adoptive T-cell therapy is clinically efficacious in the treatment of select cancers. However, it is often difficult to obtain adequate numbers of tumor-specific T cells for therapy. One method for overcoming this limitation is to generate tumor-spec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f7db054817e66c4125826ae6df7f04d
https://pubmed.ncbi.nlm.nih.gov/18690205
https://pubmed.ncbi.nlm.nih.gov/18690205
Autor:
Yian Chen, Mohamed L. Salem, Andre N. Kadima, Sabry A. El-Naggar, David J. Cole, William E. Gillanders, Mark P. Rubinstein
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 30(1)
Although cyclophosphamide (CTX) has been clearly shown to enhance active specific and adoptive immunotherapies, the mechanism(s) underlying these beneficial effects have not been clearly defined. To define the impact of CTX preconditioning on the ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7c79ccc3955ec1e962f8c7b2f2a136d
https://pubmed.ncbi.nlm.nih.gov/17198082
https://pubmed.ncbi.nlm.nih.gov/17198082
Autor:
Mohamed L. Salem, David J. Cole, John N. Vournakis, William E. Gillanders, Sabry A. El-Naggar, Mark P. Rubinstein, Andre N. Kadima, Marina Demcheva
Publikováno v:
Journal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research. 26(9)
It has become increasingly apparent that the ability to generate an optimal host immune response requires effective cross talk between the innate and adaptive components of the immune system. Pro-inflammatory cytokines, in particular those that can i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b630e9d10e497eea77ae33bfc8e8b64d
https://pubmed.ncbi.nlm.nih.gov/16978064
https://pubmed.ncbi.nlm.nih.gov/16978064
Publikováno v:
Vaccine. 24(24)
Poly (I:C), a TLR3 ligand, has shown promise as a vaccine adjuvant to CD8(+) T cell responses. The underlying mechanisms involved in creating this adjuvant response in vivo, however, have not been well defined. In this study, we explored the contribu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbc68c8c719e9dffc88ac8365aac2dfc
https://pubmed.ncbi.nlm.nih.gov/16704888
https://pubmed.ncbi.nlm.nih.gov/16704888
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 28(3)
Poly(I:C), a synthetic double-stranded RNA polymer and a TLR3 agonist, can be used as a vaccine adjuvant to enhance adaptive immunity. However, the antigen-specific CD8 T-cell response to peptide vaccination and poly(I:C) has not been clearly defined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d7c30ab0f2ad5a34e6e4917e288006b
https://pubmed.ncbi.nlm.nih.gov/15838378
https://pubmed.ncbi.nlm.nih.gov/15838378
Autor:
Andre N. Kadima, Christophe L. Nguyen, William E. Gillanders, Mohamed L. Salem, David J. Cole, Mark P. Rubinstein
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 169(9)
The systemic administration of IL-2 can act as a potent adjuvant for T cell-directed vaccine strategies. However, not only is the administration of IL-2 potentially toxic, but recent evidence suggests that it may also paradoxically limit the duration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::652ae2cdddbf7d29f79fe16a979f24bc
https://pubmed.ncbi.nlm.nih.gov/12391205
https://pubmed.ncbi.nlm.nih.gov/12391205
Autor:
Mohamed Labib Salem, C. Marcela Diaz-Montero, Yian Chen, Sabry A. EL-Naggar, Andre N. Kadima, William E. Gillanders, David J. Cole
Publikováno v:
The Journal of Immunology. 178:S80-S81
We have reported that in vivo administration of the toll-like receptor 3 ligand (TLRL) poly (I:C) induced rapid stimulation of the innate mediators, including NK cells, Mϕ, dendritic cells, and inflammatory cytokines. These effects strikingly augmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f57ca76550e9fb2f3e04ac70665edbfd
https://doi.org/10.4049/jimmunol.178.supp.48.31
https://doi.org/10.4049/jimmunol.178.supp.48.31